Compare LONA & NTIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LONA | NTIC |
|---|---|---|
| Founded | 2011 | 1970 |
| Country | United States | United States |
| Employees | 19 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Specialties |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.8M | 83.1M |
| IPO Year | N/A | 1996 |
| Metric | LONA | NTIC |
|---|---|---|
| Price | $8.12 | $8.10 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 18.8K | 12.4K |
| Earning Date | 05-08-2026 | 04-09-2026 |
| Dividend Yield | N/A | ★ 0.49% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $84,234,474.00 |
| Revenue This Year | N/A | $12.49 |
| Revenue Next Year | N/A | $7.64 |
| P/E Ratio | ★ N/A | $402.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.21 | $7.14 |
| 52 Week High | $14.21 | $10.03 |
| Indicator | LONA | NTIC |
|---|---|---|
| Relative Strength Index (RSI) | 39.98 | 51.34 |
| Support Level | $8.12 | $7.86 |
| Resistance Level | $11.44 | $8.25 |
| Average True Range (ATR) | 0.60 | 0.13 |
| MACD | -0.08 | 0.01 |
| Stochastic Oscillator | 16.59 | 60.00 |
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.
Northern Technologies International Corp is a United States-based firm that develops and markets proprietary, environmentally beneficial products and services world wide either directly or through a network of joint ventures, distributors, and agents. It operates through two segments, which include ZERUST products and services and Nature-Tec products. Its main business is providing corrosion prevention solutions that are marketed under the ZERUST brand. The company also sells a portfolio of bio-based and biodegradable (compostable) polymer resin compounds and finished products marketed under the Nature-Tec brand. The ZERUST brand generates a vast majority of the revenue for the company. The company generates the majority of its revenue in the United States.